HC Wainwright & Co. Maintains Buy on MediWound, Lowers Price Target to $5.5
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains MediWound (NASDAQ:MDWD) with a Buy and lowers the price target from $6 to $5.5.
Earnings Scheduled For November 15, 2022
Companies Reporting Before The Bell
• Alkaline Water Co (NASDAQ:WTER) is likely to report quarterly loss at $0.05 per share on revenue of $18.31 million.
MediWound Announces Formation Of Strategic Advisory Board
MediWound Ltd. (NASDAQ:MDWD), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced the establishment of a Strategic Advisory
Dow Turns Higher; Crude Oil Rises 0.7%
U.S. stocks pared some losses, with the Dow Jones turning higher toward the end of trading on Thursday.
MediWound Announces Concurrent Registered Direct And Private Placement Offerings Priced At-the-Market Of ~$30M
YAVNE, Israel, Sept. 22, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd.
Earnings Scheduled For August 9, 2022
Companies Reporting Before The Bell
• Cognition Therapeutics (NASDAQ:CGTX) is estimated to report earnings for its second quarter.
Recap Of Wednesday’s Biotech Catalysts – End Of the Day Summary
The U.S. Food and Drug Administration (FDA) has accepted for review MediWound’s (NASDAQ:MDWD) recently re-submitted Biologics License Application…
FDA Accepts MediWound’s Refiling For Severe Thermal Burns Therapy For Review
The U.S. Food and Drug Administration (FDA) has accepted for review MediWound’s (NASDAQ: MDWD) recently re-submitted Biologics License Application (BLA) for its lead asset NexoBrid for eschar removal (debridement) in adults with deep partial-thickness and/or full-thickness thermal burns.
MediWound Posts Early Data From Non-Melanoma Skin Cancer Trial
MediWound Ltd (NASDAQ:MDWD) announced initial data from eleven patients in its ongoing open-label Phase 1/2 study of MW005 for low-risk Basal…